Literature DB >> 1851428

Immune-deficient mice as models of normal and leukemic human hematopoiesis.

J E Dick1.   

Abstract

A complete understanding of the organization of the human hematopoietic stem cell hierarchy and of the molecular events regulating the stem cell developmental program has been hampered by the absence of suitable in vivo stem cell assays. Perturbations in the normal stem cell program that lead to neoplastic growth are also difficult to study because leukemic cells do not grow readily in culture. Recent advances in the transplantation of human cells into immune-deficient mice provide an unprecedented opportunity to study human hematopoiesis--both normal and abnormal--in the context of a small animal model. Here I review several of these new animal models and the basic concepts of murine and human hematopoiesis which led to their development.

Entities:  

Mesh:

Year:  1991        PMID: 1851428

Source DB:  PubMed          Journal:  Cancer Cells        ISSN: 1042-2196


  5 in total

Review 1.  The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract.

Authors:  Angela Wahl; J Victor Garcia
Journal:  J Immunol Methods       Date:  2014-06-18       Impact factor: 2.303

Review 2.  Humanized mice for HIV and AIDS research.

Authors:  J Victor Garcia
Journal:  Curr Opin Virol       Date:  2016-07-19       Impact factor: 7.090

3.  High expression of miR-9 in CD133+ glioblastoma cells in chemoresistance to temozolomide.

Authors:  Jessian L Munoz; Vivian Rodriguez-Cruz; Pranela Rameshwar
Journal:  J Cancer Stem Cell Res       Date:  2015-02-27

Review 4.  In vivo platforms for analysis of HIV persistence and eradication.

Authors:  J Victor Garcia
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

5.  The concurrent maturation of mouse and human thymocytes in human fetal thymus implanted in NIH-beige-nude-xid mice is associated with the reconstitution of the murine immune system.

Authors:  T R Kollmann; M M Goldstein; H Goldstein
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.